Good day and thank you for standing by. Welcome to the Seer Fourth Quarter and Full-Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's ...
Seer and Korea University launch a study to identify blood-based cancer biomarkers using advanced mass spectrometry and AI analytics. Seer, Inc. and Korea University have launched a groundbreaking ...
Omid C. Farokhzad, Founder, CEO & Chair of the Board, stated Q2 2025 was a pivotal quarter with "discipline, advance key commercial and product milestones and accelerate the validation and impact of ...
“In Q3, we saw robust demand and utilization for our recently launched Proteograph ONE workflow, resulting in another strong quarter for instrument shipments. Notably, we have shipped nearly three ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback